SLC11A2: a promising biomarker and therapeutic target in ovarian cancer

Ovarian cancer has the highest mortality rate among gynecologic tumors, with a 5-year survival rate of less than 25%. There is an urgent need for early diagnosis and new drugs to reduce the disease burden of ovarian cancer. The aim of this study was to investigate the effectiveness of SLC11A2 as a t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Liming, Li, Xuemei, Lai, Huiling, Sun, Tingting, Li, Xiaohui, Wu, Linxiang, Wu, Chuling, Yao, Shuzhong, Ren, Yufeng, He, Shasha, Yang, Guofen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860018/
https://www.ncbi.nlm.nih.gov/pubmed/36670142
http://dx.doi.org/10.1038/s41598-022-26789-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860018/
https://www.ncbi.nlm.nih.gov/pubmed/36670142
http://dx.doi.org/10.1038/s41598-022-26789-5

Ejemplares similares